news
NICE guidance recommends olaparib for breast and prostate cancers
PARP inhibitor olaparib has been recommended in NICE’s final draft guidance for early breast cancer and advanced prostate cancer.
List view / Grid view
olaparib
news
NICE recommends olaparib tablets for platinum-sensitive cancer patients
NICE has recommended olaparib tablets (Lynparza, AstraZeneca) for adults with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer with a BRCA1 or BRCA2 mutation.
news
Scientists identify cause of resistance to breast and ovarian cancer drug
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors...
news
FDA accepts regulatory submission for Lynparza in metastatic breast cancer
Lynparza has the potential to offer a new treatment option for patients with metastatic breast cancer...
